Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.77 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.53 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411995 | 0.91 | GRM5 (0.64) | GRM5NT5EKCNK3KCNK9KCNH2 | |
| SCHEMBL12416470 | 0.88 | GRM5 (0.78) | GRM5NT5EKCNK3KCNK9KCNH2 | |
| SCHEMBL6927318 | 0.87 | GRM5 (1.00) | GRM5MEN1KMT2A | |
| SCHEMBL2193262 | 0.87 | GRM5 (1.00) | GRM5MEN1KMT2ACSF1RNPC1 | |
| SCHEMBL6926675 | 0.87 | GRM5 (0.76) | GRM5 | |
| SCHEMBL12412012 | 0.86 | GRM5 (0.68) | GRM5NT5EKCNK3KCNK9KCNH2 | |
| SCHEMBL12412008 | 0.86 | GRM5 (0.59) | GRM5NT5EKCNK3KCNK9KCNH2 | |
| SCHEMBL12416421 | 0.85 | GRM5 (0.80) | GRM5NT5EKCNK3KCNK9KCNH2 | |
| SCHEMBL6928690 | 0.85 | GRM5 (0.72) | GRM5 | |
| SCHEMBL12504638 | 0.85 | KCNK3 (0.59) | GRM5NT5EKCNK3KCNK9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569308-B2 | Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110172247-A1 | SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172247-A1 | SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885NT5E 575/4885KCNK3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.